ICARE Social Media Post December 2021

FDA Approves PARP Inhibitor (Olaparib) Treatment for some BRCA carriers with Early Stage Breast Cancer

FDA granted priority review to Olaparib for adjuvant treatment of certain patients with high-risk breast cancer. This designation applies to use of the agent by patients with BRCA-mutated, HER2-negative, high-risk early breast cancer who receive chemotherapy before or after surgery.

For additional information, visit: https://tinyurl.com/healioFDAapproval

Permanent link to this article: https://inheritedcancer.net/post120621/